Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres








Gamme d'année
1.
Chinese Journal of Virology ; (6): 39-43, 2013.
Article de Chinois | WPRIM | ID: wpr-339977

RÉSUMÉ

To confirm the hypothesis that the high frequency sequences of high throughput sequencing are the terminal sequences of the bacteriophage genome. An adaptor of specific sequence was linked to the end of the bacteriophage T3 genomic DNA, which was then subject to high throughput sequencing; as a control, the same T3 genomic DNA without adaptor was also analyzed by high throughput sequencing. The sequencing results were examined with bioinformatics software. Similar high throughput sequencing technique was applied to analyze the genomic sequence of N4-like bacteriophage IME11. Bioinformatics study showed that the sequences tagged with adaptors were consistent with the high frequency sequences without adaptor labeling. Our analysis also indicated that the end of the T4-like phage genome had specific sequences instead of random sequences, disagreeing with the previous assertion. Evidences were provided that N4-like bacteriophage had a particular terminal sequence: the left end of the genome was unique while the right end was permuted. The high throughput sequencing technique was convenient and practical to be used to simultaneously detect the terminal sequence and the complete sequence of bacteriophage genome.


Sujet(s)
Caudovirales , Génétique , Biologie informatique , Génome viral , Séquençage nucléotidique à haut débit , Méthodes
2.
Zhonghua ganzangbing zazhi ; Zhonghua ganzangbing zazhi;(12): 437-439, 2010.
Article de Chinois | WPRIM | ID: wpr-326340

RÉSUMÉ

<p><b>OBJECTIVES</b>To construct a stable HCV-producing cell model for anti-HCV drug research.</p><p><b>METHODS</b>The HCV-ribozyme recombinant plasmid pJFH1-Rbz was constructed to generate the exact 5' and 3' ends of HCV genomic RNA by placing two self-cleaving ribozymes at both ends of the HCV JFH-1 cDNA. The plasmid was then transfected into HepG2 cells and the resultant clones were screened with G418. Subsequently, immunofluorescence and Western blot were performed to detect the expression of HCV core protein, HCV RNA level was quantitated by TaqMan real-time PCR method and HCV particles was detected by electron microscopy.</p><p><b>RESULTS</b>HCV core protein was detected in the screened cell clone, and the level of HCV RNA was up to 1000,0000 copies/ml in the culture medium. Electron microscopy showed the viral particles in the culture suspension were approximately 55 nm in diameter. IFN-treating experiment demonstrated that the HCV RNA level decreased with the increasing concentration of IFN alpha.</p><p><b>CONCLUSION</b>We constructed a stable HCV-producing cell model which can be used for anti-HCV drug research.</p>


Sujet(s)
Humains , ADN complémentaire , Génome viral , Cellules HepG2 , Hepacivirus , Génétique , Plasmides , ARN catalytique , Génétique , Transfection , Protéines du core viral , Génétique , Virion , Réplication virale
3.
Zhonghua zhong liu za zhi ; (12): 279-282, 2005.
Article de Chinois | WPRIM | ID: wpr-331171

RÉSUMÉ

<p><b>OBJECTIVE</b>To investigate the mechanisms of apoptosis induced in human hepatoma cell line SMMC7721 by plasmid pVHN constructed with Newcastle disease virus (NDV) HN gene.</p><p><b>METHODS</b>Twenty-four h after transfection with liposome-plasmid pVHN complexes in vitro, the mortality rate of SMMC7721 cells was determined by MTT staining and flow cytometry (FCM) with PI staining. The alteration of mitochondrial trans-membrane potential of the cells was detected by FCM with rhodamine 123 staining. Cell genomic DNA was detected by agarose electrophoresis. The activation of caspase-3 was assayed by its substrate color reaction.</p><p><b>RESULTS</b>Significant apoptosis was induced by transfection with plasmid pVHN into the cells for 24 h and the mortality rate was 50.0% (the mortality rate of control group was 5.2%). Genomic DNA was fragmented and mitochondrial trans-membrane potential was decreased, but caspase-3 activity increased.</p><p><b>CONCLUSION</b>Significant apoptosis in SMMC7721 cells can be induced by NDV HN gene. Apoptosis may be resulted from the decrease of mitochondrial trans-membrane potential and activation of Caspase-3.</p>


Sujet(s)
Humains , Apoptose , Physiologie , Vaccins anticancéreux , Allergie et immunologie , Carcinome hépatocellulaire , Anatomopathologie , Caspase-3 , Métabolisme , Lignée cellulaire tumorale , Protéine HN , Génétique , Tumeurs du foie , Anatomopathologie , Virus de la maladie de Newcastle , Génétique , Transfection , Vaccins à ADN , Allergie et immunologie
4.
Article de Chinois | WPRIM | ID: wpr-325323

RÉSUMÉ

<p><b>OBJECTIVE</b>Nucleic vaccine of pVVP3IL-18HN expressing apoptin gene, Newcastle disease virus HN gene and IL-18 gene were constructed to observe the combinative antitumor effect of the above three genes.</p><p><b>METHODS</b>Eukaryotic expression plasmid pVVP3IL-18HN was constructed by inserting apoptin gene and fragment comprising fused IL-18HN gene and IRES promoter into the downstream of CMV promoter of vector pVAX1. The expression of inserted gene was identified by RT-PCR, indirect immunofluorescence and Western-blot. The recombinant plasmid was introduced into Hep-2 cells by liposome, then suppression rate of Hep-2 of different time and different quantity was calculated according to MTT results.</p><p><b>RESULT</b>The recombinant plasmid of pVVP3IL-18HN suppressed Hep-2 successfully and its suppression rate was up to 61.9% with 20 microg/ml, incubation of 72 hours.</p><p><b>CONCLUSION</b>The nucleic vaccine constructed pVVP3IL-18HN had antitumor effect on Hep-2. It may can be used to the therapy and research of laryngeal carcinoma.</p>


Sujet(s)
Humains , Vaccins anticancéreux , Expression des gènes , Vecteurs génétiques , Protéine HN , Génétique , Cellules HepG2 , Interleukine-18 , Génétique , Tumeurs du larynx , Allergie et immunologie , Virus de la maladie de Newcastle , Allergie et immunologie , Plasmides , Transfection , Vaccins à ADN
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE